Can KRAS Mutation Status Guide Nivolumab Therapy in NSCLC?
This trial looked at the efficacy of nivolumab in a cohort of patients who were evaluated forKRAS mutations to test whether mutation status had an effect on outcomes.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
More News: Cancer & Oncology | Non-Small Cell Lung Cancer